ReviewReviews in endocrine & metabolic disorders2017
The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons.
Review in Reviews in endocrine & metabolic disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04012021 (EXplanted LIver and Ex-vivo Pancreatic Specimen Evaluation by 7 TESLA MRI - The EXLIPSE Study), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
EXplanted LIver and Ex-vivo Pancreatic Specimen Evaluation by 7 TESLA MRI - The EXLIPSE Study
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Treatment options for PNET liver metastases: a systematic review.World journal of surgical oncology · 2018Pooled it
- Navigating the landscape of liver transplantation in neuroendocrine tumors: A comprehensive scoping review.World journal of transplantation · 2026Article
- [Research progress on liver transplantation therapy for hepatic metastases in gastroenteropancreatic neuroendocrine tumors].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Upper limit of normothermic machine preservation of liver grafts from donation after circulatory death yet to be defined.World journal of transplantation · 2025Article
- Long-term Survival in a Child with Malignant Insulinoma After Liver TransplantationJournal of clinical research in pediatric endocrinology · 2024Article
- Transplant oncology - Current indications and strategies to advance the field.JHEP reports : innovation in hepatology · 2024Review
- SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Long-term outcomes of resection versus transplantation for neuroendocrine liver metastases meeting the Milan criteria.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Article
- An abdominal wall neuroendocrine tumor of unknown primary origin: A case report and review of the literature.Cancer reports (Hoboken, N.J.) · 2022Review
- Non-colorectal liver metastases: A review of interventional and surgical treatment modalities.Frontiers in surgery · 2022Review
- Liver Transplantation for High-Grade Primary Hepatic Neuroendocrine Tumor with Diffuse Liver Metastasis.Journal of gastrointestinal cancer · 2020Article
- Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.Journal of clinical medicine · 2019Review
- Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.Reviews in endocrine & metabolic disorders · 2018Review
- Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours.World journal of gastroenterology · 2018Review
- Liver transplantation for hilar cholangiocarcinoma (h-CCA): is it the right time?Translational gastroenterology and hepatology · 2018Article
- Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines.Reviews in endocrine & metabolic disorders · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver metastases occur in nearly half of NET patients (MNETs) and heavily affect prognosis, with 5-yr. OS around 19-38%. Although it is difficult to show outcome differences for available treatments, due to the long course of disease, surgery for MNETs remains the most effective option in terms of survival and symptom control. Since MNETs frequently present as an oligo-metastatic, liver-limited disease, unresectable in 80% of cases, liver transplantation (LT) has emerged as a potential curative treatment. Nevertheless, experience with LT for MNETs is limited and burdened by highly heterogeneous outcomes and significant recurrence rate, mostly explained by the variability of selection criteria. Several prognostic factors have been identified: extended surgery on primary tumor associated to LT, elderly patients, pancreatic primary (pNET), extensive liver involvement, poorly differentiated tumors, high Ki67 levels and short wait time to LT. A proper patients' selection based on these data (Milan NET criteria) allows a significant survival advantage over non-transplant strategies, with excellent outcomes in recent series (69-97.2% 5-yr. OS) as opposed to patients undergoing non-surgical treatments (34-50.9%). Evidence indicates LT as the best option for selected patients with MNETs. The use of organs for MNETs is therefore justified.
Indexed as
Identifiers
29359266What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.